ClinicalTrialsFinder
CompletedPhase 3ACTRN12610000046000

Treatment of Lung Adenocarcinoma by Liposomal Cisplatin

Comparison of effectiveness of Liposomal Cisplatin combined with Paclitaxel versus Cisplatin combined with Paclitaxel in patients with adenocarcinoma and undifferentiated carcinoma of the lungs.

Sponsor

George P. Stathopoulos

Enrollment

150 participants

Start Date

Sep 1, 2007

Study Type

Interventional

Conditions

Inoperable lung cancer

Summary

Liposomal Cisplatin has shown to be less toxic than Cisplatin. Dimished side effects such as nephrotoxicity and GI tract toxicity. The present study was to detect mainly the response rate between the two drugs combined with Paclitaxel.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 82 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests a new form of the chemotherapy drug cisplatin, delivered in tiny fat-based capsules (liposomes), for treating a common type of lung cancer called adenocarcinoma. It is for adults aged 18 to 82 who have been newly diagnosed and have not yet received any cancer treatment.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Liposomal Cisplatin 200 mg/m2 in 1 lt of dextrose for 8 hours infusion combined with Paclitaxel 135 mg/m2 infusion for 3 hours every 2 weeks for 9 cycles. Treatment was administered once every 2 weeks

Liposomal Cisplatin 200 mg/m2 in 1 lt of dextrose for 8 hours infusion combined with Paclitaxel 135 mg/m2 infusion for 3 hours every 2 weeks for 9 cycles. Treatment was administered once every 2 weeks (on day 1 repeated on day 15th, then 29th and so on for 9 cycles).

Locations(1)

Attica, Greece

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000046000